Cyclosporine A neurotoxicity among bone marrow transplant recipients.

abstract：:Newly introduced dopamine agonists, such as ropinirole, may offer advantages compared to such older drugs as bromocriptine in patients with advanced Parkinson's disease (PD) with response oscillations or waning efficacy. Dose equivalence of these two drugs, however, has not been well established, which may complicate ...

journal_title：Clinical neuropharmacology

authors： Giménez-Roldán S,Esteban EM,Mateo D

更新日期：2001-11-01 00:00:00

abstract：:A correlation was found among the degree of memory loss, intellectual impairment, the quantity of senile plaques, and a decrease in choline acetyltransferase and acetylcholinesterase activity in patients affected by senile dementia of the Alzheimer type. In this study, patients were subjected to a series of computeriz...

journal_title：Clinical neuropharmacology

authors： Agnoli A,Martucci N,Manna V,Conti L,Fioravanti M

更新日期：1983-01-01 00:00:00

abstract：:Despite ongoing dispute over the pathophysiologic basis of migraine, the vasospastic theory of pathogenesis has brought to the forefront a promising class of new antimigraine agents, the Ca2+ channel antagonists. Voltage-dependent Ca2+ channels, integral membrane proteins that permit extracellular Ca2+ to enter cells ...

journal_title：Clinical neuropharmacology

authors： Greenberg DA

更新日期：1986-01-01 00:00:00

abstract：:Spinal cord injury (SCI) is a devastating and common neurologic disorder that has profound influences on modern society from physical, psychosocial, and socioeconomic perspectives. Accordingly, the present decade has been labeled the Decade of the Spine to emphasize the importance of SCI and other spinal disorders. Sp...

journal_title：Clinical neuropharmacology

authors： Dumont RJ,Okonkwo DO,Verma S,Hurlbert RJ,Boulos PT,Ellegala DB,Dumont AS

更新日期：2001-09-01 00:00:00

abstract：OBJECTIVE:The pathophysiology of hallucinations in Parkinson disease is poorly understood. This study investigated the relation between visual hallucination and visual evoked potentials (VEPs) in Parkinson disease. METHODS:Nineteen patients with Parkinson disease were studied. The authors divided patients into 2 group...

journal_title：Clinical neuropharmacology

authors： Matsui H,Udaka F,Tamura A,Oda M,Kubori T,Nishinaka K,Kameyama M

更新日期：2005-03-01 00:00:00

abstract：:Six males and one female with chronic tic disorders, whose ages ranged from 12 to 31 years, were evaluated before treatment, after 1 month on placebo, after a single 10 mg nifedipine dose (three patients), and monthly while on flunarizine 10-15 mg (mean dose of 13 mg). None of the patients receiving nifedipine improve...

journal_title：Clinical neuropharmacology

authors： Micheli F,Gatto M,Lekhuniec E,Mangone C,Fernandez Pardal M,Pikielny R,Casas Parera I

更新日期：1990-02-01 00:00:00

abstract：:In a randomized double-blind study, 20 parkinsonian patients (suffering from the disease for 2-18 years), chronically treated with levodopa (500-750 mg/day for 0.5-12 years), received terguride (1 mg b.i.d.) or placebo for 4 weeks. Growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH), and insulin-li...

journal_title：Clinical neuropharmacology

authors： Martignoni E,Horowski R,Liuzzi A,Costa A,Dallabonzana D,Cozzi R,Attanasio R,Rainer E,Nappi G

更新日期：1996-02-01 00:00:00

abstract：:A case of a mentally retarded patient with sporadic paroxysmal dystonia, unresponsive to anticonvulsant therapy, is described. He had a long-standing history of neuroleptic drug intake. Trihexyphenidyl in a total daily dosage of 20 mg totally suppressed the crises. ...

journal_title：Clinical neuropharmacology

authors： Micheli F,Fernandez Pardal M,de Arbelaiz R,Lehkuniec E,Giannaula R

更新日期：1987-08-01 00:00:00

abstract：:A 51-year-old woman became depressed following the death of her father-in-law. She was given 50 mg of milnacipran a day. One week after starting milnacipran, she developed parkinsonism. The milnacipran was increased to 100 mg/d, resulting in a situation where her symptoms of parkinsonism and depression worsened, which...

journal_title：Clinical neuropharmacology

authors： Muraoka T,Oku E,Sugataka K,Yamada S

更新日期：2008-09-01 00:00:00

abstract：:Four to 10% of patients with Parkinson disease and chronically treated with levodopa undergo an addictionlike behavioral disturbance named dopamine dysregulation syndrome (DDS). This article suggests that patients with Parkinson disease could be especially prone to develop DDS due to the dopamine deficiency and the "p...

journal_title：Clinical neuropharmacology

authors： Linazasoro G

更新日期：2009-01-01 00:00:00

abstract：:Data on a twice-daily dosage schedule with moclobemide in the treatment of depression is limited. In this study, moclobemide 150 mg twice daily (b.i.d.) was compared to two different three-times-daily (t.i.d.) regimens with total daily dosages of 300 and 450 mg, respectively, over a 6-week period. The study was random...

journal_title：Clinical neuropharmacology

authors： Gagiano CA,Hart GA,Bodemer W,Schall R

更新日期：1994-01-01 00:00:00

abstract：:The purpose of this study was to evaluate the effect of amantadine sulfate infusion on the N30 component of the median nerve short-latency somatosensory evoked potentials (SSEPs) in patients with Parkinson's disease (PD). Twenty patients with advanced PD and severe motor fluctuations received a 6-day course of amantad...

journal_title：Clinical neuropharmacology

authors： Bostantjopoulou S,Katsarou Z,Georgiadis G,Zafiriou D,Kazis A

更新日期：2002-03-01 00:00:00

abstract：:A significant proportion of the interindividual variance in human fatness is attributable to genetic factors. This fact is indicated (inter alia) by studies of identical twins demonstrating that the degree of efficiency with which the body uses excess dietary energy for fat storage is, to a considerable extent, inheri...

journal_title：Clinical neuropharmacology

authors： Van Itallie TB

更新日期：1988-01-01 00:00:00

abstract：:Monoamine oxidase type B (MAO-B) is the predominant isoform responsible for the metabolic breakdown of dopamine in the brain. Selective inhibition of brain MAO-B results in elevation of synaptosomal dopamine concentrations. Data have been reported regarding the selective MAO-B inhibitors, rasagiline and selegiline, fo...

journal_title：Clinical neuropharmacology

authors： Fernandez HH,Chen JJ

更新日期：2007-05-01 00:00:00

abstract：OBJECTIVE:We present 3 new cases of psychotic symptoms in patients with adult attention-deficit/hyperactivity disorder while regularly treated with a stimulant therapy with methylphenidate. METHODS:Existing literature about this theme is reviewed, and potential mechanisms are discussed. RESULTS AND CONCLUSIONS:Medica...

journal_title：Clinical neuropharmacology

authors： Kraemer M,Uekermann J,Wiltfang J,Kis B

更新日期：2010-07-01 00:00:00

abstract：:The selective estrogen receptor modulator, tamoxifen, is extensively used for the endocrine treatment of all stages of hormone receptor-positive breast cancer. Tamoxifen is a mainly inactive prodrug, necessitating metabolism by the cytochrome P450 (CYP450) pathway, predominantly the Cytochrome P450 2D6 (CYP2D6), into ...

journal_title：Clinical neuropharmacology

authors： De Berardis D,Brucchi M,Serroni N,Valchera A,Fornaro M,Mazza M,Martinotti G,Di Giannantonio M

更新日期：2014-01-01 00:00:00

abstract：OBJECTIVE:The use of amobarbital in the Wada test varied between epilepsy centers, with no unified dosing or protocols available in the literature to standardize its use. We aimed to determine the dose of amobarbital in the presurgical evaluations of patients with temporal lobe epilepsy. METHODS:A retrospective study ...

journal_title：Clinical neuropharmacology

authors： Bajammal S,Babtain F,Alqadi K,Baeesa S,Kurdi K,Madani N,Al Said Y

更新日期：2020-11-01 00:00:00

abstract：OBJECTIVE:Safety and efficacy of botulinum neurotoxin type A preparation NT 201 (Xeomin, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany) were investigated over 52 weeks in a double-blind, randomized trial with 32 male volunteers. METHODS:Electroneurographic assessments with surface electrodes were performed aft...

journal_title：Clinical neuropharmacology

authors： Wohlfarth K,Müller C,Sassin I,Comes G,Grafe S

更新日期：2007-03-01 00:00:00

abstract：:Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder. This disorder was characterized by aggressive agitation, self injurious behavior, insomnia, and incessant motor activity occurring between 10 and 55 days after initiation of drug therapy. The affected c...

journal_title：Clinical neuropharmacology

authors： Sheth RD,Goulden KJ,Ronen GM

更新日期：1994-08-01 00:00:00

abstract：:Preclamol, the (-)enantiomer of 3-PPP (= 3(3-hydroxyphenyl)-N-n-propyl piperidine), has a selective dopamine autoreceptor- and postsynaptic mixed agonist-antagonist profile. Its action on patients with disabling on-off parkinsonian fluctuations has been studied and compared with those of placebo and subcutaneous apomo...

journal_title：Clinical neuropharmacology

authors： Pirtosek Z,Merello M,Carlsson A,Stern G

更新日期：1993-12-01 00:00:00

abstract：BACKGROUND AND PURPOSE:Treatment of chronic insomnia with nightly hypnotics is efficacious, but discontinuation is recommended after 1 month, less than the average disease duration. This study was undertaken to determine the efficacy of intermittent administration. PATIENTS AND METHODS:A double-blind study was carried...

journal_title：Clinical neuropharmacology

authors： Parrino L,Smerieri A,Giglia F,Milioli G,De Paolis F,Terzano MG

更新日期：2008-01-01 00:00:00

abstract：:The results of pharmacokinetic studies of two recent 5-HT uptake inhibitors, zimelidine and fluoxetine, have pointed to the inadequacy of open-dose rising studies for establishing the most appropriate dose of new antidepressants. High plasma concentrations of the active metabolites, norzimelidine and norfluoxetine, we...

journal_title：Clinical neuropharmacology

authors： Montgomery SA,Baldwin D,Shah A,Green M,Fineberg N,Montgomery D

更新日期：1990-01-01 00:00:00

abstract：:In this study, the hemodynamic and neurochemical effects of lisuride, a dopamine agonist with serotoninergic properties, have been evaluated in de novo parkinsonian patients and in elderly subjects with mild cognitive impairment. Blood pressure (BP), heart rate (HR), and urinary catecholamine (CA) fluctuations through...

journal_title：Clinical neuropharmacology

authors： Micieli G,Martignoni E,Bono G,Cavallini A,Rossi F,Horowski R,Nappi G

更新日期：1989-10-01 00:00:00

abstract：OBJECTIVE:Although hormone replacement therapy (HRT) improves menopausal depressive symptoms, women unresponsive to HRT need an antidepressant drug as an effective adjunctive therapy. The aim of this study was to assess whether the herbal medicine Unkei-to has an impact on HRT-resistant menopausal depressive symptoms a...

journal_title：Clinical neuropharmacology

authors： Koike K,Ohno S,Takahashi N,Suzuki N,Nozaki N,Murakami K,Sugiura K,Yamada K,Inoue M

更新日期：2004-07-01 00:00:00

abstract：OBJECTIVE:A multicenter open-label clinical trial was conducted to evaluate the clinical usefulness of topiramate (TPM) as primary or adjunctive therapy for infantile spasms in the postmarketing period in China. METHODS:Thirty-four centers participated in the trial. Patients included in the study had 1 or more seizure...

journal_title：Clinical neuropharmacology

authors： Zou LP,Lin Q,Qin J,Cai FC,Liu ZS,Mix E,Topiramate Study Group.

更新日期：2008-03-01 00:00:00

abstract：:Clozapine is known to be beneficial for the treatment of dopamine agonist-induced psychotic states in patients with Parkinson's disease (PD). Many reports have suggested that it may also be efficacious for the treatment of parkinsonian tremor. We describe a patient with schizophrenia in whom early-onset PD appeared af...

journal_title：Clinical neuropharmacology

authors： Orr G,Munitz H,Hermesh H

更新日期：2001-03-01 00:00:00

abstract：:Dehydroepiandrosterone (DHEA) is an important neurosteroid and has demonstrated efficacy in the improvement of mood and energy. The authors previously reported the efficacy of DHEA augmentation in the management of negative, depressive, and anxiety symptoms of schizophrenia. To characterize further the effects of DHEA...

journal_title：Clinical neuropharmacology

authors： Strous RD,Maayan R,Kotler M,Weizman A

更新日期：2005-11-01 00:00:00

abstract：:Flumazenil is a benzodiazepine receptor antagonist. It is currently used mainly in the anaesthetic and emergency rooms to reverse the effect of exogenous benzodiazepines. Its use in a variety of experimental animal models and in human neuropsychiatric disorders continues to generate a wealth of information on the poss...

journal_title：Clinical neuropharmacology

authors： Malizia AL,Nutt DJ

更新日期：1995-06-01 00:00:00

abstract：OBJECTIVES:Our study aimed to identify the association of norepinephrine transporter gene (SLC6A2), synaptosomal-associated protein of the 25-kDa gene (SNAP-25), and latrophilin 3 gene (LPHN3) with osmotic-controlled release oral delivery system methylphenidate (OROS MPH) treatment response. METHODS:One hundred thirty...

journal_title：Clinical neuropharmacology

authors： Song J,Kim SW,Hong HJ,Lee MG,Lee BW,Choi TK,Lee SH,Yook KH

更新日期：2014-09-01 00:00:00

abstract：:Chronic posthypoxic myoclonus is characterized by myoclonic jerks that are specifically triggered by action. It is a rare but devastating sequela of hypoxic encephalopathy. We report a 42-year-old female patient with treatment-resistant chronic posthypoxic myoclonus, which improved with administration of the drug agom...

journal_title：Clinical neuropharmacology

authors： González de la Aleja J,Saiz-Díaz RA,De la Peña P

更新日期：2012-09-01 00:00:00